anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention provides a method that is used for reducing the nitrogen oxide in a mammal. Compared with the prevention method of the prior art (for example, the effect that is used for generating the enzyme of the nitrogen oxide is prevented), the present invention adopts a removal method, which is to integrate the excess nitrogen oxide in the living body to an appropriate nitrogen-oxide removal agent. The generated compound facilitates the harmlessness of the nitrogen oxide and the final extrusion of the nitrogen oxide from the urine of the main body. In addition, the present invention also provides a compound and a formula, which are used for the method. The present invention also relates to a method that is used as a method to cure the main body that suffers the inflammation and/or the communicable disease and reduce the nitrogen oxide of a living body. Feeding the nitrogen oxide removal agent containing the dithiocar-bamate to the main body required the cure, the removal agent is reacted with the nitrogen oxide NO that is generated in the living body to form the stable compound of dithiocar-bamate - metal-nitrogen oxide; the compound containing the nitrogen oxide is filtered by the kidney, and is concentrated in the urine, and finally discharged from the main body, thereby reducing the nitrogen oxide in the living body.
PROBLEM TO BE SOLVED: To provide a device capable of adjusting skin-conductible electric conductivity, which is provided with a small beam diameter so as to enable irradiating only a certain specified effective point and also which is small and lightweight with simple configuration and also operated by means of a dry battery. SOLUTION: An electric bulb 2, a medicine box 9, crystal 11, a medicine box 3 and filters 12, 13 and 14 are arranged in a cylinder 1. The medicine box 3 is divided into three upper, middle and lower steps and the respective steps are partitioned into eight small rooms. Various medicines (including a herb medicine), food and minerals, etc., are contained in the respective small rooms in the three steps and they are sealed by partitioning plates 5-7 so as to prevent them from scattering. The medicine box 9 is also partitioned into the eight small rooms inside, the same medicines, etc., are respectively contained in the same way, the medicines are sealed by an upper lid or a lower lid so as to prevent them from scattering. A through hole 10 is formed in the center of the medicine boxes 9 and 3.  A light beam generated from the electric bulb 2 passes through the through hole in the center of the medicine box 10 and the through hole in the center of crystal 11 and the medicine box 3 so as to go towards the filters.
Prone position: Thanks to a high-resolution ultrasound and a 5 MHz curved probe, we will use the ultrasound technique described by Greher et al to reach the target points. Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol) to observe them using the standard Fluoroscopic method. Wrongly positioned needles will be correctly repositioned and these patients will be excluded from ODI and VAS scale statistics.
The MBCT intervention will consist of group conducted meditative practices, lasting 2 hours per week for 8 weeks. Patients will be invited to try various techniques during sessions (brief silent meditations, guided meditations, body scans, gentle arm movement exercises).
Children with asthma and obesity are more likely to have lower vitamin D levels, but the optimal replacement dose is unknown in this population. The objective of this study is identifying a vitamin D dose in children with obesity-related asthma that safely achieves serum vitamin D levels of ≥ 40 ng/mL. This prospective multisite randomized controlled trial recruited children/adolescents with asthma and body mass index ≥ 85% for age/sex. Part 1 (dose finding), evaluated 4 oral vitamin D regimens for 16 weeks to identify a replacement dose that achieved serum vitamin D levels ≥ 40 ng/mL. Part 2 compared the replacement dose calculated from part 1 (50,000 IU loading dose with 8,000 IU daily) to standard of care (SOC) for 16 weeks to identify the proportion of children achieving target serum 25(OH)D level. Part 1 included 48 randomized participants. Part 2 included 64 participants. In Part 1, no SOC participants achieved target serum level, but 50-72.7% of participants in cohorts A-C achieved the target serum level. In part 2, 78.6% of replacement dose participants achieved target serum level compared with none in the SOC arm. No related serious adverse events were reported. This trial confirmed a 50,000 IU loading dose plus 8,000 IU daily oral vitamin D as safe and effective in increasing serum 25(OH)D levels in children/adolescents with overweight/obesity to levels ≥ 40 ng/mL. Given the critical role of vitamin D in many conditions complicating childhood obesity, these data close a critical gap in our understanding of vitamin D dosing in children.
In patients with scar in the hearts after heart attacks, the risk for dangerous abnormal heart rhythms, including sudden death is high. This is because dead muscle fibers are replaced by scar tissue, creating a physiological condition promoting abnormal heart rhythms.These abnormal heart rhythms are called ventricular arrhythmias or ventricular tachycardias. In these patients, ablation procedures can be helpful, however the recurrence rate of arrhythmias after ablation remains unacceptably high. The primary reason for this high recurrence rate is nonspecific mapping methodologies for identifying the heart area responsible for these arrhythmias. Therefore, new methods for increasing the specificity of mapping have been the subject of significant research for many years, however implementation of these methods in clinical practice has been challenged by limited technologies. Recently, a new mapping technology named "parallel mapping" has been developed, received FDA approval and is routinely utilized at the Cleveland Clinic. However, the workflow of using parallel mapping, and the efficacy of ablation using this technology have not been evaluated.
###  Teratogenic Effects 

Pregnancy Category C. Teratology studies with spironolactone have been carried out in mice and rabbits at doses of up to 20 mg/kg/day. On a body surface area basis, this dose in the mouse is substantially below the maximum recommended human dose and, in the rabbit, approximates the maximum recommended human dose. No teratogenic or other embryotoxic effects were observed in mice but the 20 mg/kg dose caused an increased rate of resorption and a lower number of live fetuses in rabbits. Because of its anti-androgenic activity and the requirement of testosterone for male morphogenesis,spironolactone may have the potential for adversely affecting sex differentiation of the male during embryogenesis. When administered to rats at 200 mg/kg/day between gestation days 13 and 21 (late embryogenesis and fetal development), feminization of male fetuses was observed. Offspring exposed during late pregnancy to 50 and 100 mg/kg/day doses of spironolactone exhibited changes in the reproductive tract including dose-dependent decreases in weights of the ventral prostate and seminal vesicle in males, ovaries and uteri that were enlarged in females, and other indications of endocrine dysfunction, that persisted into adulthood. There are no adequate and well-controlled studies with spironolactone in pregnant women. Spironolactone has known endocrine effects in animals including progestational and antiandrogenic effects. The antiandrogenic effects can result in apparent estrogenic side effects in humans, such as gynecomastia. Therefore, the use of spironolactone in pregnant women requires that the anticipated benefit be weighed against the possible hazards to the fetus.
Traumatic Brain Injury (TBI) induces neuroinflammatory response that can initiate epileptogenesis, which develops into epilepsy. Recently, we identified anti-convulsive effects of naltrexone, a mu-opioid receptor (MOR) antagonist, used to treat drug addiction. While blocking opioid receptors can reduce inflammation, it is unclear if post-TBI seizures can be prevented by blocking MORs. Here, we tested if naltrexone prevents neuroinflammation and/or seizures post-TBI. TBI was induced by a modified Marmarou Weight-Drop (WD) method on 4-week-old C57BL/6J male mice. Mice were placed in two groups: non-telemetry assessing the acute effects or in telemetry monitoring for interictal events and spontaneous seizures both following TBI and naltrexone. Molecular, histological and neuroimaging techniques were used to evaluate neuroinflammation, neurodegeneration and fiber track integrity at 8 days and 3 months post-TBI. Peripheral immune responses were assessed through serum chemokine/cytokine measurements. Our results show an increase in MOR expression, nitro-oxidative stress, mRNA expression of inflammatory cytokines, microgliosis, neurodegeneration, and white matter damage in the neocortex of TBI mice. Video-EEG revealed increased interictal events in TBI mice, with 71% mice developing post-traumatic seizures (PTS). Naltrexone treatment ameliorated neuroinflammation, neurodegeneration, reduced interictal events and prevented seizures in all TBI mice, which makes naltrexone a promising candidate against PTS, TBI-associated neuroinflammation and epileptogenesis in a WD model of TBI.
Two-stage contraceptive agents contg. in the first stage a gestagen and in the second stage a gestagen plus oestrogen, all with customary carriers, taste-correcting and/or filling agents. Prefd. agents contain nor-ethisterone acetate as gestagen in the first stage and cyproterone acetate as gestagen in the 2nd stage combined with 17alpha-ethinyloestradiol as the oestrogen. The prepns. may be used as sequential contraceptives. The use of a two-stage sequence reduces the oestrogen intake, gives better cycle-control and reduces the rate of intermediate bleeding. The use of two different gestagens in stages 1 and 2 reduces or eliminates the gestagen side-effects.
The invention relates to a method for producing virus-like particles on the basis of polyoma viruses. The invention can be used in medical fields such as gene therapy, vaccine development and diagnosis as well as in veterinary medicine. The aim of the invention is to develop a method for producing virus-like particles for gene therapy, diagnosis and vaccine development. This method should enable a highly efficient production of non-infectious, endotoxin-free virus-like particles which are suitable for humane applications. The inventive method relates to the application of a yeast high-expression system which permits the production of large quantities of virus-like particles on the basis of the main capsid protein VP1 of polyoma viruses. By extracting said particles from yeast cells, these virus-like particles are endotoxin-free and suitable for humane applications.
INTRODUCTION: Population aging is a problem that has affected most countries in the world. Poor-quality sleep is a common complaint among the elderly. Foot baths are a method of heat therapy and are performed as an independent nursing care in different departments. The present study was conducted with the aim of investigating the effects of foot baths with spa on improving the sleep quality of the elderly.
METHODS: This research is a systematic review. We systematically searched six databases, including Google Scholar, PubMed, Web of Science, Scopus, Embase, and the World Health Organization databases, to retrieve the related articles based on the keywords used in our search strategy from 2010 to March 2023.
RESULT: Finally, 10 articles were included in this study. All studies were randomized controlled trial (RCTs) and semi-experimental. In all 9 studies, the positive effects of the foot bath were reported. In 9 studies, the effect of foot baths with water above 40 degrees Celsius was reported. The PSQR questionnaire was used in most of the studies.
CONCLUSION: The total findings of this study showed that due to the high prevalence of sleep problems in the elderly, foot baths with warm water can be used as an easy, simple, and safe nursing intervention to improve sleep quality. Therefore, it can be used in nursing homes and hospitals. It is also a non-pharmacological and inexpensive nursing intervention that can be implemented by the elderly themselves after training by community health nurses.
Thus, current practice for treating psychotic depression is to combine an antidepressant with an antipsychotic. However, there are limitations to this approach. The rate of response is still lower than in other forms of major depression (Janicak et al., 2001). The rate of noncompliance is higher in this group; and the incidence of adverse effects related to the antipsychotic is increased (Janicak et al., 2001). As a result, studies have examined alternative treatments. The present study proposes to examine quetiapine's antipsychotic and mood stabilizing properties for the treatment of a major depressive disorder with psychotic features Subjects will be randomized to either quetipine monotherapy, quetiapine and citalopram; or haloperidol and citalopram.
Active arm subjects will be treated intravaginally with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μs, dot spacing 1000 μm and the smart stack parameter from 1 to 3. For the vulva, the dot power will be reduced to 26 watts, dwell time 800 μs, dot spacing 800 μm and the smart stack parameter of 1.
An apparatus and method for applying a beneficial agent to the skin is disclosed in one embodiment of the invention as including first and second chemical reactants, each being compatible with the skin. The first and second chemical reactants react with one another to generate a beneficial agent and enhance the permeability of the skin (e.g., by generating heat). The beneficial agent may then be applied to the skin while the permeability of the skin is enhanced. In selected embodiments, the first chemical reactant includes one or more metals, or alloys thereof, that are compatible (i.e., not harmful) with the skin. Similarly, in selected embodiments, the second chemical reactant may include water. In certain embodiments, the beneficial agent generated by the first and second chemical reactants includes an antioxidant such as hydrogen.
In a process for increasing the prodn. of antibodies from a patient (US 3719182), the lymph collected from the patient is centrifuged to separate the lymph cells by forcing the lymph into a thin zone of constant radius so that the cells form a thin relative to the cell size) layer within the zone. The centrifuge pref. comprises a cylindrical core within a cylindrical housing, forming a narrow annular space into which the lymph is introduced, the separated fluid being removed via radial openings in the core. The lymph cells are sepd. with the minimum of damage, the cell film obtained can be readily suspended in physiological saline soln. and thus returned to the patient.
The currently recommended treatment for children with overweight or obesity (OW/OB), family-based behavioral treatment (FBT), results in sustained weight loss for only 1/3 of children. Attention-Deficit Hyperactivity Disorder (ADHD) is one of the most common neurobehavioral disorders in children and is characterized by difficulties in Executive Function (EF). Substantial research suggests higher rates of OW/OB in children with ADHD; thus, children with OW/OB and ADHD are likely to have greater difficulties with EF and achieving success in FBT. The proposed study aims to develop a parent-based behavioral treatment enhanced with EF training (PBT-EF) to improve treatment outcomes for children with comorbid OW/OB and ADHD. The treatment will be administered to parents in 18 group sessions over 5 months. Parents and children will be assessed at baseline, post-treatment, and 3-month follow-up. Assessments will include body mass index (BMI), assessments of executive function, and behavioral questionnaires. This study could provide a novel model to treat OW/OB in children with ADHD, and could inform clinical decision making regarding obesity treatment.
Participants will receive a standard referral to an in-person MOUD treatment appointment, which typically occurs within 24-72 hours. They also receive a bus pass to cover transportation (both directions), as well as an appointment reminder card.
Intravenous infusion of AVID200 over 1 hour administered every three weeks. Starting dose for dose escalation.
The L1 cell adhesion molecule (L1) has demonstrated a range of beneficial effects in animal models of spinal cord injury, neurodegenerative disease, and ischemia; however, the role of L1 in TBI has not been fully examined. Mutations in the L1 gene affecting the extracellular domain of this type 1 transmembrane glycoprotein have been identified in patients with L1 syndrome. These patients suffer from hydrocephalus, MASA (mental retardation, adducted thumbs, shuffling gait, aphasia) symptoms, and corpus callosum agenesis. Clinicians have observed that recovery post-traumatic brain injury (TBI) varies among the population. This variability may be explained by the genetic differences present in the general population. In this study, we utilized a novel mouse model of L1 syndrome with a mutation at aspartic acid position 201 in the extracellular domain of L1 (L1-201). We assessed the impact of this specific single nucleotide polymorphism (SNP) localized to the X-chromosome L1 gene on recovery outcomes following TBI by comparing the L1-201 mouse mutants with their wild-type littermates. We demonstrate that male L1-201 mice exhibit significantly worse learning and memory outcomes in the Morris water maze after lateral fluid percussion (LFP) injury compared to male wild-type mice and a trend to worse motor function on the rotarod. However, no significant changes were observed in markers for inflammatory responses or apoptosis after TBI.
This review summarizes the impact of systemic and ocular inflammatory disorders on diabetes mellitus (DM) and diabetic retinopathy (DR). Local inflammation is a key pathology in diabetic retinopathy (DR) and is also an evolving target for clinical therapy. The legacy effects of local inflammation at the intracellular level make DR a persistent self-driven vicious process. Ocular inflammation is accompanied as well as incited by systemic inflammation due to diabetes mellitus (DM) itself. Over the years, a multitude of studies have evaluated the impact of systemic inflammatory disorders (SIDs, like rheumatoid arthritis, lupus, psoriasis, etc.) and anti-inflammatory drugs prescribed for managing them on manifestations of DM. Recent studies have indicated increased insulin resistance to be a result of chronic inflammation, and the anti-inflammatory drugs to have a protective effect towards DM. Very few studies have evaluated the impact of SIDs on DR. Furthermore, the evidence from these studies is conflicting, and while local anti-inflammatory therapy has shown a lot of clinical potential for use in DR, the results of systemic anti-inflammatory therapies have been inconsistent. The impact of local ocular inflammation due to uveitis on DR is a crucial aspect that has not been evaluated well at present. Initial pre-clinical studies and small-sized clinical reports have shown a strong and positive relationship between the presence of uveitis and the severity of DR as well as its progression, while larger cross-sectional patient surveys have refuted the same. The long term impact of ocular inflammation due to uveitis on DR needs to be studied while adjusting for confounders.
The present invention relates to compositions and methods for preventing pneumococcal infection. In particular, the invention relates to identification of the major reception for Streptococcus pneumoniae on activated human cells, and diagnostic and therapeutic conpositions and methods based thereon. In particular, the invention relates to the discovery that platelet activating factor (PAF) receptor is an adhesive ligand for pneumococcal adherence to activated lung epithelial and venous endothelial (i.e., host) cells. Accordingly, the present invention is directed to a method for preventing or treating an infection with Streptococcus pneumoniae by administering an antogonist of platelet activating factor receptor. The invention further relates to recognition that adherence to activated cells also involves a carbohydrate ligand found on such activated cells. Thus, a method for inhibiting pneumococcal adherence may further comprise administering an amount of carbohydrate containing an N-acetyl-D-glucosamine motif. It has been found that resting lung epithelial and venous endothelial cells bear two classes of receptors containing different carbohydrate motifs. Thus, the invention further provides for administering an amount of a second carbohydrate selected from the group consisting of a carbohydrate containing a disaccharide N-acetyl-D-galactosamine .beta.1-4Gal motif, a disaccharide N-acetyl-D-galactosamine .beta.1-3Gal motif, and a mixture thereof. In addition, the invention provides pharmaceutical compositions comprising such agents that inhibit binding of pneumococci to human cells. In a specific example, platelet activating factor receptor antagonists and disaccharides are shown to inhibit binding of pneumococci to activated lung epithelial cells and venous endothelial cells, as well as cells transfected with the platelet activating factor receptor, in vitro.
The invention provides a traditional Chinese medicinal composition for treating Alzheimer-type diseases, wherein the traditional Chinese medicinal composition comprises the following traditional Chinese medicinal raw materials forming active ingredients according to the weight: 7.5g of radix polygoni multiflori preparata, 5g of cultivated land, 7.5g of epimedium herb, 5g of cynomorium songaricum and 5g of dogwood. After 107 light-moderate AD patients are treated for 24 weeks and 48 weeks, the comparison result of MMSE (mini-mental state examination) curative effects are as follows: for the effective rate with 48-week treatment, the western-medicine control group is 55.77% and the Chinese-medicine group is 70.91%. According to the above results, for treating the Alzheimer-type diseases, the traditional Chinese medicinal composition for is better than the donepezil. When being applied clinically, the traditional Chinese medicinal composition is directly taken by is mixed with water, and is simple in use. The traditional Chinese medicine particles are packaged by an aluminium-foil bag without easy moisture absorption, the size is small and the carrying is convenient. The invention provides a new treatment direction for treating the Alzheimer-type diseases and has larger clinic application value.
Suppressor of fused (SUFU) is widely regarded as a key negative regulator of the sonic hedgehog (SHH) morphogenic pathway and a known tumor suppressor of medulloblastoma (MB). However, we report here that SUFU expression was markedly increased in 75% of specimens compiled in a tissue array comprising 49 unstratified MBs. The SUFU and GLI1 expression levels in this MB array showed strong positive correlation, which was also identified in a large public data set containing 736 MBs. We further report that increasing Sufu gene dosage in mice caused preaxial polydactyly, which was associated with the expansion of the Gli3 domain in the anterior limb bud and heightened Shh signaling responses during embryonic development. Increasing Sufu gene dosage also led to accelerated cerebellar development and, when combined with ablation of the Shh receptor encoded by Patched1 (Ptch1), promoted MB tumorigenesis. These data reveal multifaceted roles of SUFU in promoting MB tumorigenesis by enhancing SHH signaling. This revelation clarifies potentially counterintuitive clinical observation of high SUFU expression in MBs and may pave way for novel strategies to reduce or reverse MB progression.